Cvs Health Corporation · NYSE:CVS
Cvs Health — Q4 2024 Earnings Presentation
13 slides from Cvs Health's earnings presentation, Feb 12, 2025
Slide 1: Fourth quarter 2024 earnings conference call
Fourth quarter 2024 February 12, 2025 Earnings conference call J. David Joyner Thomas F. Cowhey President and Executive Vice President and Chief Executive Officer Chief Financial Officer 1 ©2025 CVS Health and/or one of its affiliates. Confidential and proprietary.
Slide 2: Cautionary statement concerning forward-looking statements
Cautionary statement concerning forward-looking statements This presentation includes forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation (“CVS Health”). By their nature,
Slide 3: Financial highlights
Financial highlights Delivered revenue growth of 4.2% and adjusted EPS of $1.19 in the fourth quarter of 2024. Issued initial 2025 adjusted EPS guidance of $5.75 to $6.00. FOURTH QUARTER FULL-YEAR 2025 Our Priorities Financial Results Company Guidance To be America’s most 4.2% At least $385.9B trust
Slide 4: Accelerating opportunities to drive integrated value
Accelerating opportunities to drive integrated value We are Increase in Aetna® members covered by ~12% Caremark® (YoY change) demonstrating progress towards In-Home Health Evaluations key measures of completed by Signify Health (Full-Year 2024) >3M success across the Active users of newly redesigned
Slide 5: Building a world of health around every consumer
OUR VISION Building a world of health around every consumer 5 ©2025 CVS Health and/or one of its affiliates. Confidential and proprietary.
Slide 6: Our Strategic Imperatives
Our Strategic Imperatives Grow Build Enable Create Empower our core business diverse national care consumers’ health seamless engagement our people and delivery and value- with care and and personalized culture based care capabilities coverage capabilities experiences across across local points all
Slide 7: Consolidated Results
Consolidated Results in billions, Business highlights except per share amounts Q4 2024 Q4 2023 Successfully completed our three- year store closure plan and are Total Revenues $97.7 $93.8 progressing further footprint optimization in 2025. Adjusted Operating Income $2.73 $4.23 Maintained greater tha
Slide 8: 2025 Consolidated Guidance
2025 Consolidated Guidance GUIDANCE RESULTS in billions, except per share Full-Year 2025 Full-Year 2024 Business highlights amounts and tax rate Guidance Results Issued initial full-year 2025 adjusted Total Revenues At least $385.9 $372.8 EPS guidance within the range of $5.75 to $6.00. Adjusted Ope
Slide 9: Superior assets. Superior care. Superior value.
Superior assets. Superior care. Superior value. 9 ©2025 CVS Health and/or one of its affiliates. Confidential and proprietary. ©2025 CVS Health and/or one of its affiliates. Confidential and proprietary. 9
Slide 10: Health care benefits
Health care benefits in billions, except MBR and membership Q4 2024 Q4 2023 Business highlights Total Revenues $33.0 $26.7 Fourth quarter adjusted operating loss of $439 million was lower than Adjusted Operating Income ($0.44) $0.68 the prior year quarter, primarily driven Total Medical Membership b
Slide 11: Health services
Health services in billions, except pharmacy claims Q4 2024 Q4 2023 Business highlights Total Revenues $47.0 $49.1 Fourth quarter adjusted operating income decreased ~5% year over year, Adjusted Operating Income $1.76 $1.86 primarily driven by continued pharmacy client price improvements Pharmacy Cl
Slide 12: Pharmacy & consumer wellness
Pharmacy & consumer wellness in billions, except prescriptions filled Q4 2024 Q4 2023 Business highlights Total Revenues $33.5 $31.2 Fourth quarter adjusted operating income decreased ~13% year over Adjusted Operating Income $1.76 $2.03 year, primarily driven by continued pharmacy reimbursement pres
Slide 13: Footnotes
Footnotes Fourth quarter 2024 1. Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. 2. Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operat